Biocon to acquire Viatris' remaining Biologics stake for full integration via share swap

• Biocon to fully integrate Biocon Biologics (BBL) as a wholly-owned subsidiary.
• This involves acquiring Viatris' remaining stake in BBL for $815 million via a share swap.
• The deal values Biocon Biologics at $5.5 billion, with completion expected by March 31, 2026.
• Biocon plans to raise up to ₹4,500 crore (approx. $500 million) through a qualified institutional placement (QIP).
• The integration aims to simplify Biocon's structure and enhance BBL's strategic and financial flexibility for its global biosimilars portfolio.

Why It Matters: Biocon's full integration of Biocon Biologics simplifies structure, aids global expansion.